MUC16 and cancer: For example, in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) trial of blood cancer antigen CA125 measurements and transvaginal ultrasound scans, the observed nonsignificant 10.2% reduction in late-stage (III and IV) ovarian cancer incidence in the screening versus no screening cohort (p = 0.084) was substantially attenuated when it came to disease-specific mortality (nonsignificant 4.4% reduction) with a median of 15 years of follow-up [36], which led some to conclude that mortality endpoints are necessary in screening trials.